Fundraising FoxKeystone — 2026 Investments
1 investments dated 2026 · listed companies and verified rows first · show all
CERo Therapeutics develops engineered T cell immunotherapies designed to treat cancer by combining innate and adaptive immune mechanisms; the company is conducting clinical trials of CER-1236, an autologous T cell product targeting TIM-4 ligand, in acute myeloid leukemia and other hematological malignancies, with planned expansion into solid tumors including non-small cell lung cancer and ovarian cancer.
San Francisco, US
Daniel Mark Corey(Director)Lawrence Corey(Executive Officer, Director)Jordan Thomas Corey(Executive Officer)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.